Bank of America CEO Brian Moynihan is not worried about an economic slowdown, saying the U.S. consumer is still in a strong place.Banksread more
Target CEO Brian Cornell says he's encouraged by Trump's decision to postpone some consumer-oriented tariffs that were supposed to start Sept. 1.Retailread more
Corporate debt recently passed the $1 trillion mark in a continuing sign of global financial displacement.Marketsread more
President Trump insists the economy is healthy and says the only thing holding U.S. growth back is the Federal Reserve.Marketsread more
In a second-round of tweets aimed at the U.S. central bank, the president asked, "WHERE IS THE FEDERAL RESERVE?"Marketsread more
J.P. Morgan Chase customers will no longer be able to pay with their phones in stores beginning next year.Marketsread more
Gluskin Sheff's David Rosenberg predicts one of the strongest parts of the U.S. economy will disappoint Wall Street and lead to a market meltdown.Futures Nowread more
Target shares opened at record high after the retailer beat second-quarter earnings expectations and boosted its full-year estimates.Retailread more
Sanders' sweeping proposal would make it easier for workers to join unions and end the so-called right-to-work laws recently favored by the GOP.2020 Electionsread more
Germany has sold a 30-year bond with a 0% interest rate for the first time on Wednesday.Marketsread more
JPMorgan health care expert Lisa Gill shared her thoughts on the drug pricing debate as well as potential stock picks in an exclusive interview with CNBC PRO's Mike Santoli.
"As we think about drug pricing, [pharmacy benefit managers] don't set the price at the end of the day," explained Gill. "The drug distributors distribute a product and, yes, when there's drug price inflation they make a fee off of the average wholesale price of the drug."
"When you think about what the pharmacy benefit management companies are trying to do, they're trying to manage and negotiate a better price."
Gill is managing director of U.S. healthcare technology at JPMorgan, where she's been a member of the health care team since 1998. Her coverage includes health care distribution, pharmacy benefit managers and drug retail. Prior to her work at JPMorgan, she was part of an audit group specializing in health care facilities at Ernst & Young.
As a part of her interview, Gill also revealed some of her favorite names in the health care space.
"We have historically have liked the PBM industry and we think that CVS is very well positioned because of that," she said. "The other one I like – I like Lab Corp – and I think Lab Corp is well positioned. It's a lab as well as on the CRO side so if we think about incremental innovation on the side of new products coming to markets, that's another name that we like."